"We are hoping this is something that we can repurpose quickly for those affected by these variants,” says Heather Christofk, PhD.
Investigators have found that inhibition of the purine salvage pathway in hereditary leiomyomatosis and renal cell cancer (HLRCC) tumors reduced growth of the tumors in vivo, signaling a possible new treatment strategy for patients with kidney cancer, according to findings published in Cancer Discovery.1,2
The targeting of this pathway is based on the study findings that a number of genetic variants previously of unknown significance rely on the purine salvage pathway for growth, and they predispose patients to HLRCC, which increases the risk of developing aggressive kidney cancer.
“Based on these findings, not only can we now better characterize a lot of patients who have a variant and did not previously know if they really had an increased risk of kidney cancer, we can possibly repurpose this well-tolerated drug to be a rapidly translatable treatment strategy. And we are hoping this is something that we can repurpose quickly for those affected by these variants,” said senior author Heather Christofk, PhD, in a news release on the findings.2 Christofk is the director of basic and translational research at the University of California, Los Angeles (UCLA) Jonsson Comprehensive Cancer Center.
For the study, the investigators assessed the activity and level of fumarate present among 74 variants of the fumarate hydratase gene that were previously of unknown significance. Among those, over half were found to be inactive and likely contributing to growth of the disease.
Cells lines of fumarate hydratase gene variants of varying degrees of activity were then assessed, showing different levels of fumarate. Upon analysis, the investigators uncovered that an accumulation of fumarate due to fumarate hydratase deficiency disrupts pathways for cell growth, causing the cells to rely on the purine salvage pathway for proliferation instead.
“One way to stop tumor growth from occurring, is to potentially target this pathway. We found that these tumors rely on this alternative pathway, which uses nutrients from the environment in order to synthesize nucleotides. Generating nucleotides is essential for the tumor cells to replicate and sustain growth,” explained lead author Blake Wilde, MD, in the news release.2 Wilde is a postdoctoral fellow in the Christofk laboratory at UCLA.
When the investigators analyzed the response of cell cultures and mice to the use of 6-mercaptopurine, which targets the purine salvage pathway, they found that the drug led to a reduction in the number of nucleotides and tumor growth.
The authors concluded, “These findings suggest pathogenicity of patient-associated FH variants and reveal purine salvage as a targetable vulnerability in FH-deficient tumors.”
1. Wilde BR, Chakraborty N, Matulionis N, et al. FH variant pathogenicity promotes purine salvage pathway dependence in kidney cancer. Cancer Discov. Published online May 31, 2023. Accessed July 19, 2023. doi:10.1158/2159-8290.CD-22-0874
2. Gene mutations linked to hereditary kidney cancer predisposition but potential Achilles’ heel identified. News release. University of California, Los Angeles (UCLA), Health Sciences. July 12, 2023. Accessed July 19, 2023. https://www.newswise.com/articles/gene-mutations-linked-to-hereditary-kidney-cancer-predisposition-but-potential-achilles-heel-identified?sc=mwhr&xy=10016681